CTI BioPharma Statistics
Total Valuation
Specificity has a market cap or net worth of 6.12 million. The enterprise value is 8.24 million.
| Market Cap | 6.12M |
| Enterprise Value | 8.24M |
Important Dates
The next estimated earnings date is Wednesday, August 20, 2025.
| Earnings Date | Aug 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Specificity has 13.61 million shares outstanding. The number of shares has increased by 12.88% in one year.
| Current Share Class | 13.61M |
| Shares Outstanding | 13.61M |
| Shares Change (YoY) | +12.88% |
| Shares Change (QoQ) | +18.80% |
| Owned by Insiders (%) | 52.60% |
| Owned by Institutions (%) | n/a |
| Float | 5.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.88 |
| PB Ratio | -8.76 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -11.47 |
| EV / Sales | 9.26 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.01
| Current Ratio | 0.01 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -13.38 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -52.72% |
| Return on Invested Capital (ROIC) | -114.65% |
| Return on Capital Employed (ROCE) | -222.41% |
| Revenue Per Employee | 111,292 |
| Profits Per Employee | -89,875 |
| Employee Count | 8 |
| Asset Turnover | 1.12 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -76.57% in the last 52 weeks. The beta is 1.31, so Specificity's price volatility has been higher than the market average.
| Beta (5Y) | 1.31 |
| 52-Week Price Change | -76.57% |
| 50-Day Moving Average | 0.63 |
| 200-Day Moving Average | 0.78 |
| Relative Strength Index (RSI) | 46.83 |
| Average Volume (20 Days) | 2,960 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.50 |
Income Statement
In the last 12 months, Specificity had revenue of 890,332 and -718,997 in losses. Loss per share was -0.06.
| Revenue | 890,332 |
| Gross Profit | 327,500 |
| Operating Income | -668,997 |
| Pretax Income | -718,997 |
| Net Income | -718,997 |
| EBITDA | -662,378 |
| EBIT | -668,997 |
| Loss Per Share | -0.06 |
Balance Sheet
| Cash & Cash Equivalents | n/a |
| Total Debt | 1.67M |
| Net Cash | -1.67M |
| Net Cash Per Share | -0.12 |
| Equity (Book Value) | -699,206 |
| Book Value Per Share | -0.08 |
| Working Capital | -1.25M |
Cash Flow
| Operating Cash Flow | -315,374 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 36.78%, with operating and profit margins of -75.14% and -80.76%.
| Gross Margin | 36.78% |
| Operating Margin | -75.14% |
| Pretax Margin | -80.76% |
| Profit Margin | -80.76% |
| EBITDA Margin | -74.40% |
| EBIT Margin | -75.14% |
| FCF Margin | n/a |
Dividends & Yields
Specificity does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.88% |
| Shareholder Yield | n/a |
| Earnings Yield | -11.74% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Specificity has an Altman Z-Score of -6.61 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.61 |
| Piotroski F-Score | 2 |